Signal intensity in the dentate nucleus after cumulative dose of Gd-EOB-DTPA: First results of a prospective longitudinal study
Issue title: Selected papers of the 39th Conference of the German Society for Clinical Microcirculation and Hemorheology, 6-7 November 2020, Hannover, Germany
Guest editors: B. Hiebl, A. Krüger-Genge and F. Jung
Affiliations: [a] Department of Internal Medicine, Hospital Kempten, Kempten, Germany
| [b] Department of Radiology, Hospital Potsdam, Potsdam, Germany
| [c] Center for Clinical Trials, University Hospital Regensburg, Regensburg, Germany
| [d] Department of Radiology, University Hospital Regensburg, Regensburg, Germany
| [e] Department of Radiology, Hospital Braunschweig, Braunschweig, Germany
Correspondence:
[*]
Corresponding author: Katharina Michalik, Department of Internal Medicine, Hospital Kempten, Kempten, Germany. E-mail: katharina.e.michalik@gmail.com.
Abstract: Gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) is a hepatocyte-specific, linear ionic contrast agent for MRI. In comparison to other linear contrast agents Gd-EOB-DTPA is excreted equally through liver and kidneys. This prospective longitudinal study investigates the signal intensity (SI) in the dentate nucleus (DN) on unenhanced T1-weighted images after repetitive application of Gd-EOB-DTPA. 46 patients were included into the study and 107 MRI examinations were performed. Statistical analysis of 25 patients showed no significant correlation between cumulative dose of Gd-EOB-DTPA and SI change and between the DN/Pons ratiolast and the mean DN/Pons ratiofirst. Subgroup analysis however revealed a significant correlation for one out of two readers. Gd-EOB-DTPA deposition could not be proven in the framework of this study.
